Note: This document is a translation of a part of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Consolidated Financial Results for the Nine Months Ended December 31, 2023 [Japanese GAAP]

February 13, 2024

Company name: SUNCORPORATION Stock exchange listing: Tokyo Code number: 6736 URL: https://www.sun-denshi.co.jp Representative: Ryusuke Utsumi President and Representative Director Contact: Yoshimi Kimura Representative and Executive managing director Phone: +81-52-756-5981 Scheduled date of filing quarterly securities report: February 13, 2024 Scheduled date of commencing dividend payments: -Availability of supplementary briefing material on quarterly financial results: No Schedule of quarterly financial results briefing session: No

(Amounts of less than one million yen are rounded down.)

1. Consolidated Financial Results for the Nine Months Ended December 31, 2023 (April 1, 2023 to December 31, 2023)(1) Consolidated Operating Results(% indicates changes from the previous corresponding period.)

	Net sales		Operating	profit	Ordina		profit	Profit attribu owners of	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions	of yen	%	Millions of yen	%
December 31, 2023	7,467	(78.4)	218	-	(4	,267)	-	(4,145)	-
December 31, 2022	34,497	31.1	(1,874)	-	13	,566	322.3	6,305	321.2
(Note) Comprehensive income	e: Nine mor	nths ended	1 December 31	, 2023:	¥	(1	76) millio	on [-%]
	Nine mor	nths ended	l December 31	, 2022:	¥	11,	959 millio	on [273.	5%]
	Basic ea per sl		Dilute	d earnings share	per				
Nine months ended		ľ	Yen		Yen				

(Note) Diluted net income per share for the third quarter of the fiscal year ending March 31, 2024 is not shown in the above table, because net income per share was negative although there are residual shares.

252.09

(2) Consolidated Financial Position

December 31, 2023

December 31, 2022

		Total assets	Net assets		Capital adequacy ratio
As of		Millions of yen	Millions	of yen	%
December 31, 2023		42,190	33	3,519	79.2
March 31, 2023		41,767	3:	5,013	83.6
(Reference) Equity:	As of	December 31, 2023:	¥	33,4	06 million
	As of	March 31, 2023:	¥	34,9	08 million

(186.29)

266.28

(Note) In the first quarter of the current fiscal year, the Company finalized the provisional accounting treatment for the business combination, and the consolidated financial position for the fiscal year ending March 31, 2023 reflects the details of the finalization of the provisional accounting treatment.

2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2023	-	0.00	-	20.00	20.00
Fiscal year ending March 31, 2024	-	0.00	-		
Fiscal year ending March 31, 2024 (Forecast)				40.00	40.00

(Note) Revision to the forecast for dividends announced most recently: No

3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2024(April 1, 2023 to March 31, 2024)

(% indicates changes from the previous corresponding period.)

	Net s	sales	Operating profit		
	Millions of yen	%	Millions of yen	%	
Full year	10,000	(73.3)	10		
	\sim 11,000	~(70.6)	~ 100	-	
(Note) Revision to th	e financial results forecast	announced mos	t recently: No	0	

(Note) Revision to the financial results forecast announced most recently:

It is difficult to reasonably estimate the impact of changes in the fair value of contingent consideration, certain restricted stock and derivative warrant liabilities of our equity method investment Cellebrite DI Ltd. The Company has not yet determined the fair value of the restricted stock and derivative warrant liability.

* Notes:

(1) Changes in significant subsidiaries during the nine months ended December 31, 2023 (changes in specified subsidiaries resulting in changes in scope of consolidation): No

(2) Accounting policies adopted specially for the preparation of quarterly consolidated financial statements: No

(3) Changes in accounting policies, changes in accounting estimates and retrospective restatement

- 1) Changes in accounting policies due to the revision of accounting standards: No
- 2) Changes in accounting policies other than 1) above: No
- 3) Changes in accounting estimates: No

4) Retrospective restatement: No

(4) Total number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares):

December 31, 2023:	24,007,728 shares
March 31, 2023:	23,998,828 Shares

2) Number of treasury shares at the end of the period:				
December 31, 2023:	1,793,177	shares		
March 31, 2023:	1,366,387	Shares		

3) Average number of shares outstanding during the period:	
Nine months ended December 31, 2023:	22,253,162 shares
Nine months ended December 31, 2022:	23,681,288 shares

Quarterly financial statements are not subject to a quarterly review by a certified public accountant or firm of accountants. ×ו

※ Explanation of the appropriate use of earnings guidance and other special disclosures

The forward-looking statements in this document, including earnings guidance, are based on information currently available to the Company and certain assumptions that the Company believes are reasonable. Actual results could differ materially as a result of various factors.